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Abstract
7-Nitroindazole (7-NI) inhibits neuronal nitric oxide synthase in vivo and reduces l-DOPA-induced dyskinesias in a rat model of 
parkinsonism. The aim of the present study was to determine if the anti-dyskinetic effect of 7-NI was subject to tolerance after 
repeated treatment and if this drug could interfere with the priming effect of l-DOPA. Adult male Wistar rats (200-250 g) with 
unilateral depletion of dopamine in the substantia nigra compacta were treated with l-DOPA (30 mg/kg) for 34 days. On the 1st 
day, 6 rats received ip saline and 6 received ip 7-NI (30 mg/kg) before l-DOPA. From the 2nd to the 26th day, all rats received 
l-DOPA daily and, from the 27th to the 34th day, they also received 7-NI before l-DOPA. Animals were evaluated before the 
drug and 1 h after l-DOPA using an abnormal involuntary movement scale and a stepping test. All rats had a similar initial motor 
deficit. 7-NI decreased abnormal involuntary movement induced by l-DOPA and the effect was maintained during the experiment 
[before 7-NI, median (interquartile interval), day 26: 16.75 (15.88-17.00); day 28: 0.00 (0.00-9.63); day 29: 13.75 (2.25-15.50); 
day 30: 0.5 (0.00-6.25); day 31: 4.00 (0.00-7.13), and day 34: 0.5 (0.00-14.63), Friedman followed by Wilcoxon test, vs day 26, 
P < 0.05]. The response to l-DOPA alone was not modified by the use of 7-NI before the first administration of the drug (l-DOPA 
vs time interaction, F1,10 = 1.5, NS). The data suggest that tolerance to the anti-dyskinetic effects of a neuronal nitric oxide 
synthase inhibitor does not develop over a short-term period of repeated administration. These observations open a possible 
new therapeutic approach to motor complications of chronic l-DOPA therapy in patients with Parkinson’s disease.
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Nitric oxide (NO) is a gas synthesized by the NO syn-
thase (NOS) enzyme that diffuses locally in the central ner-
vous system to promote vasodilatation and the modulation 
of neuronal cells, acting as an “atypical neurotransmitter” 
(1-3). There are three types of NOS: neuronal (nNOS) 
and endothelial and inducible NOS (4). The principal form 
expressed in the brain is nNOS and its expression is re-
stricted to neurons.
It has been proposed that NO modulates motor behavior 
(5-7). NOS inhibitors inhibit hyperlocomotion induced by 
dopamine agonists in mice and rats (1,8,9). NOS inhibitors 
also induce catalepsy after systemic or intrastriatal injection, 
an effect similar to those observed after application of D2 
receptor antagonists (5,10). Tolerance has been reported 
to occur within 4-5 days of continuous treatment with NOS 
inhibitors in rodents (5,10,11). The phenomenon of toler-
ance is characterized by impaired responsiveness to the 
NOS inhibitors, which is, in turn, demonstrated by reduced 
cataleptic effect that appears after continuous use. NOS 
inhibitors-induced tolerance to other drugs that induce 
catalepsy (e.g., haloperidol) is termed cross-tolerance 
(5,10,11). Although the mechanisms underlying the phe-
nomenon of NOS inhibitor development of tolerance are still 
poorly defined (5), it may be an important obstacle for the 
eventual clinical use of these compounds in motor-related 
disorders particularly if it concerns therapeutic effects rather 
than side effects.
Dopaminergic denervation may trigger aberrant neuro-
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plastic changes in the striatum, which could interfere with 
the processing of movement-related information (12-22). 
L-DOPA is the most effective symptomatic treatment for 
Parkinson’s disease, but its chronic administration leads 
to the development of motor complications expressed as 
fluctuations in clinical response and appearance of abnormal 
involuntary movements also called l-DOPA-induced dyski-
nesias (12). The mechanisms underlying this phenomenon 
are unclear (13). Also, it has been suggested that the very 
first molecular events thought to be responsible for the 
establishment of dyskinesia are generally grouped under 
the term of “priming”. Priming is classically defined as the 
process by which the brain becomes sensitized such that 
administration of a dopaminergic therapy modifies the 
response to subsequent dopaminergic treatments (22). 
The emergence of abnormal motor responses to repetitive 
exposure to dopaminergic drugs only occurs after dopamine 
depletion (13). The authors suggest that dyskinesia and 
priming are members of the same continuum, dyskinesia 
developing with chronicity of the treatment (22).
In recent years, non-dopaminergic symptomatic thera-
pies have been extensively sought for ameliorating l-DOPA-
induced dyskinesias (14-16). We have recently shown that 
7-nitroindazole (7-NI), a preferential nNOS inhibitor, is able 
to decrease abnormal involuntary movements (AIMs) in 
l-DOPA-treated rats subjected to unilateral 6-hydroxydo-
pamine (6-OHDA) lesions of the striatal dopaminergic 
innervation (17). This model has been extensively used 
to investigate l-DOPA-induced dyskinesias (18-20). It is 
still unknown, however, if, similar to its cataleptic effects, 
repeated treatment with 7-NI would also induce tolerance 
to the anti-dyskinetic effect after repeated administration 
(5,11,21). Therefore, the main objective of the present study 
was to determine if the repeated (8 days) administration 
of 7-NI would interfere with its anti-dyskinetic effects in an 
l-DOPA-induced dyskinesia model. Another objective of 
the present study was to determine if pre-treatment with 
7-NI injection before the first l-DOPA administration would 
interfere with the subsequent l-DOPA-induced dyskinesias, 
which may have important implications for the therapeutic 
use of this agent.
Material and Methods
Animals
Adult male Wistar rats (200-250 g) were housed in 
groups of 2 or 3 per cage in a temperature-controlled room 
(±25°C), under a 12-h light-dark cycle, with free access to 
food and water. All experiments were conducted according 
to the principles and procedures described by the Guidelines 
for the Care and Use of Mammals in Neuroscience and 
Behavioral Research (ILAR, USA) and to the Guidelines 
of the School of Medicine of Ribeirão Preto (University of 
São Paulo, Brazil). This research project, the institution’s 
animal housing conditions and experimental procedures 
were approved by the local Animal Ethics Committee 
(protocol No. 101/2009). All efforts were made to minimize 
animal number. The behavioral test was always performed 
from 4:00 to 6:00 pm.
6-Hydroxydopamine lesion
Stereotaxic surgery was performed as described (23). 
Rats were anesthetized with tribromoethanol (0.25 mg/kg 
ip, Sigma-Aldrich, USA) and received a single injection of 
6-OHDA (Sigma-Aldrich, 16 μg in 3 µL saline containing 
0.05% ascorbic acid) into the right medial forebrain bundle 
at the following coordinates (24) relative to bregma: an-
teroposterior: -4.4 mm; lateral: +1.2 mm; dorsoventral: -8.2 
mm. The toxin was infused at the rate of 1 µL/min, and the 
cannula was left in place for 3 min before withdrawal. To 
limit the damage to noradrenergic neurons, desipramine 
hydrochloride (25 mg/kg ip, Sigma-Aldrich) and pargyline 
(40 mg/kg ip, Sigma-Aldrich) were administered 30 min 
before 6-OHDA injection. Rats were placed in clean cages 
on warming pads to recover from surgery, after which they 
were returned to group housing.
Drugs 
L-DOPA (Prolopa dispersive, Hoffman-LaRoche, Brazil) 
plus benserazide-HCl (7.5 mg·kg-1·day-1) were dissolved in 
physiological saline and given orally by gavage at the dose 
of 30 mg·kg-1·day-1. 7-NI (Sigma-Aldrich) was dissolved in 
50% DMSO-saline solution and administered ip at the dose 
of 30 mg/kg 30 min prior to l-DOPA intake. The doses were 
based on a previous study using a similar protocol (17). All 
solutions were prepared immediately prior to use and given 
in a volume of 2 mL/kg body weight.
Behavioral tests
Abnormal involuntary movements. A trained observer 
blind to treatment assessed each rat for the presence of 
the following AIMs (25): axial: lateral flexion and axial rota-
tion of the neck and trunk towards the side contralateral to 
the lesion; limb: repetitive, rhythmic jerky movements or 
dystonic posturing of the forelimb on the side contralateral 
to the lesion; orolingual: tongue protrusion without the 
presence of food or other objects; locomotor: locomotion 
to the contralateral side of lesion (18,20). The scores were: 
0, absent; 1, present for less than half of the observation 
time; 2, present for more than half of the observation time; 
3, continuous but interrupted by strong sensory stimuli, or 
4, continuous and not interrupted by strong sensory stimuli. 
Different amplitude scores (ranging from 0, minimal dis-
placement, to 4, maximal displacement) were assigned to 
forelimb and axial movements. The amplitude of axial AIMs 
was rated according to the lateral deviation (or torsion) of 
an animal’s neck and trunk from the longitudinal axis of its 
body, while the amplitude of limb AIMs was rated based on 
both the magnitude of paw/limb translocation and on the 
visible involvement of distal versus proximal muscle groups 
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(25). Borderline scores (0.5, 1.5, 2.5, and 3.5) were allowed 
in order to increase the sensitivity of the rating. AIMs were 
assessed during the pre-test (pre-drug) period and 1 h 
after l-DOPA administration, for 1 min, and this was always 
the first test to be done. The final score was calculated as 
the sum of all individual movements analyzed (theoretical 
maximum score = 24 per evaluation).
Forward stepping test. This is a modified version of the 
stepping test originally proposed by Olsson et al. (26). Rats 
were held by the rear part of their torso with one hand with 
their hind limbs lifted and one forepaw held steady along its 
trunk by the hand of the experimenter. Then, the animal was 
moved forward across a table for a distance of 90 cm within 
12 s (27). During this interval, the numbers of adjusting steps 
of the weight-bearing forepaw compensating for the straight 
ahead movement of the body were counted. Each forepaw 
was tested three times and for each animal the test was 
begun randomly with the right or left forepaw. The average 
number of adjusting steps performed in the three trials for 
each forepaw was used for analysis of motor performance. 
The performance of each animal was defined according 
to the relative asymmetry in the motor performance of the 
forepaws. For this purpose, we calculated a left/right (L/R) 
index of the number of adjusting steps for each animal. An 
L/R index below 1.0 indicates lower performance with the 
left forepaw. The animal performance is expressed as the 
average L/R index obtained in the pre-test (pre-drug) and 
1 h after l-DOPA intake (post-drug) and this was always the 
second test to be done.
Tissue processing
Twenty-four hours after the last test, rats were deeply 
anesthetized with urethane (25 mg/kg, Sigma-Aldrich) and 
then rapidly perfused transcardially with 250 mL cold saline 
and 400 mL 4% paraformaldehyde (Sigma-Aldrich) in 0.1 M 
phosphate buffer, pH 7.4. Brains were immediately removed, 
fixed in 4% paraformaldehyde for 24 h, cryoprotected in 30% 
sucrose solution, snap frozen in isopentane (-40°C, Sigma), 
and stored at -70°C until use. The tissues were cut into 40-
μm sections with a freezing microtome. Sections through 
the striatum and substantia nigra compacta (SNc) were 
collected in 10 mM phosphate-buffered saline containing 
0.02% sodium azide and stored at 4°C until use. 
Immunohistochemistry
Immunohistochemistry was performed using a stan-
dard peroxidase-based method (28). Randomly sampled 
sections were incubated with a tyrosine hydroxylase (TH) 
antibody (1:2000, Pel Freez, USA) overnight at 4°C followed 
by a biotinylated secondary antibody (Vectastain ABC kit, 
Vector Laboratories, USA) and HRP-conjugated streptavidin 
(Vectastain ABC kit, Vector Laboratories). The sections 
were developed using diaminobenzidine (Sigma-Aldrich) 
as the chromogen. The slices were mounted on slides 
and coverslipped for microscopic observation. Structure 
localization was determined with the help of the Paxinos 
and Watson atlas (24). Images containing TH immunostain-
ing were digitally captured with an Olympus DP70 camera 
connected to the microscope.
Experimental design
Twenty-one days after the stereotaxic surgery all rats 
were subjected to the stepping test (N = 20). Only 6-OHDA-
lesioned rats presenting an L/R index lower than 0.60 (N = 
12) were included in the study. 
Rats were divided into two well-matched groups (N = 6/
group) according to L/R index and received either vehicle 
(2 mL/kg, ip; vehicle/l-DOPA group) or 7-NI (30 mg/kg, ip; 
7-NI/l-DOPA group) followed 30 min later by l-DOPA (30 
mg/kg + 7.5 mg/kg of benserazide, by gavage). From the 
second day on, all animals started receiving single daily 
administrations of l-DOPA for an additional 24 days. From 
day 27 to 34, they received an ip injection of 7-NI 30 min 
before the daily l-DOPA intake (30 mg/kg; Figure 1). Mea-
surements of AIM scores were performed at days 1, 5, 13, 
26, 28, 29, 30, 31, and 34 of treatment. The stepping test 
was performed at days 1, 5, 13, 26, 29, and 34 of treat-
ment (Figure 1).
Statistical analysis 
Data are reported as means ± SEM. Data from the step-
ping test were analyzed by repeated measure multifactorial 
analysis of variance, with the factors being groups (vehicle 
and 7-NI), time and l-DOPA (before and after). Specific 
Figure 1. Diagram summarizing the order of the treatments and behavioral tests. Tests started 3 weeks after 6-OHDA lesion. Abnormal 
involuntary movements (AIMs) and stepping tests were assessed on day 1 after acute administration of vehicle/l-DOPA or 7-NI/l-DOPA. 
AIMs were assessed at chronic times during l-DOPA (from days 2 to 26) or 7-NI/l-DOPA (from days 27 to 34) administration. Histologi-
cal procedures were performed on day 35 of treatment. 6-OHDA = 6-hydroxydopamine; 7-NI = 7-nitroindazole.
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MANOVA was also performed to determine the effects of 
vehicle versus 7-NI treatment on the first day and to com-
pare the effects of l-DOPA on the last administration alone 
(day 26) versus the subsequent administration under the 
influence of 7-NI (from day 27 on). In case of significant 
interactions, post hoc comparisons were made using the 
Sidak test.
The effectiveness of l-DOPA in inducing AIMs at each 
assessment point was verified by the non-parametric 
Wilcoxon test. AIMs induced by l-DOPA were analyzed by 
the Mann-Whitney (first day) or Friedman test followed, 
when significant, by the Wilcoxon test for pairwise com-
parisons. The level of significance was set at P < 0.05 in 
all analyses.
Results
Rats with 6-OHDA lesions (N = 12) showed a complete 
absence of immunochemical reaction TH in the right striatum 
and in the SNc ipsilateral to the lesion (Figure 2). 
On the first day, l-DOPA caused a significant improve-
ment in the forward stepping test (F1,10 = 7.6, P = 0.02) and 
this effect was not modified by 7-NI (treatment factor, F1,10 
= 0.27, treatment versus l-DOPA, F1,10 = 0.67, NS; Figure 
3). No difference between the groups treated with 7-NI or 
vehicle on day 1 was found in subsequent measurements 
(treatment factor, F1,10 = 0.38 NS). As a consequence, the 
results were shown as a single group. 
The effect of l-DOPA was maintained throughout the 
experiment (F1,10 = 53.06, P < 0.001) and did not change 
along time (time factor, F5,6 = 2.75, P = 0.12, NS; l-DOPA 
versus time, F5,6 = 0.98, NS; Figure 3). Comparison of the 
effects of l-DOPA on day 26 (before 7-NI) and days 29 and 
34 (after 7-NI) showed that 7-NI treatment did not modify 
the effects of l-DOPA (l-DOPA versus time interaction, F1,10 
= 1.5, NS; Figure 3).
L-DOPA induced AIMs in all measurements (Wilcoxon 
test, P < 0.05) except those made on day 28 (P = 0.068; 
Figure 4). 7-NI decreased AIMs induced by l-DOPA on 
day 1 (Mann-Whitney test, P = 0.005; Figure 5). Similar 
to the stepping test, no difference between groups treated 
with 7-NI or vehicle on day 1 was found in subsequent 
measurements (P > 0.05) and the results are shown as a 
single group. l-DOPA effects increased from day 1 to days 
Figure 2. Photomicrograph of a cross-section through the stria-
tum (A) and mesencephalon (B) of a representative unilateral 
6-hydroxydopamine-lesioned rat with absence of tyrosine hy-
droxylase immunoreactive fibers/cells. CPu = caudate-putamen; 
acb = accumbens nuclei; VTA = ventral tegmental area; SNc = 
substantia nigra compacta.
Figure 3. Effects of l-DOPA (30 mg/kg) administration on step-
ping test performance of 6-OHDA-lesioned rats (N = 12). The 
stepping test performance is reported as means (+ SEM) left/
right paw (L/R) index obtained before and 1 h after l-DOPA in-
take. From day 1 to day 26 the animals received only l-DOPA. 
Starting on day 27 until day 34 they received an ip injection of 
7-NI (30 mg/kg) 30 min before l-DOPA administration. 6-OHDA 
= 6-hydroxydopamine; 7-NI = 7-nitroindazole. *P < 0.05 vs pre-
drug (MANOVA).
Figure 4. Effects of l-DOPA (30 mg/kg) administration on total 
abnormal involuntary movements (AIMs) of 6-OHDA-lesioned 
rats (N = 12). AIMs were scored 60 min before or after l-DOPA in-
take at days 5, 13, 26, 28, 29, 30, 31, and 34 of treatment. From 
day 1 to day 26 the animals received only l-DOPA. Starting on 
day 27 until day 34 they received an ip injection of 7-NI (30 mg/
kg) 30 min before l-DOPA administration. Data are reported as 
median ± interquartile interval. 6-OHDA = 6-hydroxydopamine; 
7-NI = 7-nitroindazole. *P < 0.05 vs pre-drug (Wilcoxon signed 
rank test), #P < 0.05 vs day 26 (Friedman followed by Wilcoxon 
test).
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5, 13, and 26 (Friedman test followed by the Wilcoxon test; 
P < 0.05). 7-NI induced a significant decrease in l-DOPA-
induced AIMs that was maintained until the last measure-
ment (Friedman test followed by the Wilcoxon test, versus 
day 26; P < 0.05).
Discussion
The present results showed that repeated treatment 
with 7-NI was able to decrease l-DOPA-induced dyskinesia 
in a model of Parkinson’s disease. The above mentioned 
disorder requires chronic treatment and thus repeated drug 
applications.
Unilateral lesions induced by 6-OHDA injections into 
the medial forebrain bundle have been extensively used to 
investigate the neurobiology of Parkinson’s disease (18,20). 
As indicated by TH immunohistochemistry, in the present 
study this experimental approach was able to induce severe 
striatal dopamine denervation. 
The motor impairments caused by these lesions can be 
measured by the forward stepping test and are reflected as 
an asymmetry between adjusting steps from the lesioned 
and non-lesioned sides (27). Accordingly, unpublished re-
sults (Padovan-Neto FE, Del Bel EA) from our laboratory 
have shown that an L/R index lower than 0.60 indicates a 
93.4% probability of reflecting a severe right striatal dop-
aminergic depletion (>95%). This result was confirmed by 
TH immunohistochemistry. As shown in Figure 3, l-DOPA 
was able to improve motor performance, increasing the L/R 
index throughout the experiment.
Our experiment reproduced a previously reported model 
(17) of l-DOPA-induced dyskinesias in hemiparkinsonian 
rats that used a daily dosage of l-DOPA about three times 
higher than that usually taken by patients with Parkinson’s 
disease, and the drug is given to animals all at once by 
gavage. Because of this, our animals presented significant 
AIMs at the first l-DOPA intake (17). These motor complica-
tions are clinically relevant and the mechanisms underlying 
them are still not completely understood (29). It is argued 
that a significant lack of presynaptic dopaminergic termi-
nals in the striatum would enhance the variability of striatal 
dopamine levels due to loss of capacity to locally uptake 
l-DOPA and store dopamine (30). Probably, the main sites 
of decarboxylation of exogenous l-DOPA to dopamine, 
when nigrostriatal dopaminergic neurons are damaged, are 
the serotonergic striatal terminals (29,31). This alternative 
pathway is probably poorly regulated and may result in an 
aberrant handling of l-DOPA in the striatum. 
There is also evidence that non-physiologic pulsatile 
striatal dopaminergic stimulation induces activation of 
nuclear signaling pathways that leads to the development 
of postsynaptic plastic changes in basal ganglia circuits 
that could cause an imbalance of cortical-striatal loops and 
facilitate abnormal involuntary movements (29). Indirect 
striatopallidal projections may also be abnormally active, 
probably due to excessive glutamatergic excitation after 
striatal dopaminergic denervation (32). Drugs that block 
either N-methyl-D-aspartate (NMDA) or alpha-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) recep-
tors tend to ameliorate dyskinesias in Parkinson models 
and patients (29). 
Nitrergic mechanisms may also contribute to the 
pathogenesis of l-DOPA-induced dyskinesias. Animal 
experiments have suggested that striatal dopaminergic 
lesions and chronic treatment with l-DOPA increase the 
synthesis of NO in basal ganglia (23,33-35), while the 
cerebrospinal fluid concentration of nitrate and nitrite is 
elevated in patients with Parkinson’s disease receiving 
dopamine replacement (36). The NO second messenger 
cyclic guanosine monophosphate (cGMP) is increased 
in the serum of Parkinson’s disease patients (37) and is 
regulated by l-DOPA itself (33). Chronic l-DOPA treatment 
causes overexpression of FosB/ΔFosB in neurons of the 
striatal direct output pathway and in NOS interneurons in 
lesioned areas of the striatum (35,38). Confirming a previ-
Figure 5. Effects of l-DOPA (30 mg/kg) administration on total 
abnormal involuntary movements (AIMs) of 6-OHDA-lesioned 
rats (N = 12) on the first day of treatment. AIMs were scored 60 
min before or after l-DOPA intake. Thirty minutes before l-DOPA 
administration the animals (N = 6/group) received ip injections 
of vehicle or 7-NI (30 mg/kg). Data are reported as median ± 
interquartile interval. 6-OHDA = 6-hydroxydopamine; 7-NI = 7-ni-
troindazole. *P < 0.05 (Mann-Whitney test).
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subsequent challenge with dopamine agonists. Moreover, 
dyskinesia and priming have been proposed to share simi-
lar mechanisms, with dyskinesia developing with chronic 
treatment (22). We evaluated how “priming”, a phenomenon 
displaying neurochemical and behavioral features peculiar 
to a sensitized abnormal motor response in dopamine-
denervated rats, depends on the pre-treatment with 7-NI 
injection before the first l-DOPA administration. Because 
we wanted to study this effect, we did not use the rotational 
behavior induced by amphetamine or apomorphine as an 
indicator for striatal dopamine depletion. Nevertheless, in 
the present study, treatment with 7-NI (30 mg/kg) before 
the first dose of l-DOPA did not affect priming magnitude. 
This result indicates that NOS inhibition does not seem 
to play a fundamental role in determining the outcome of 
subsequent motor responses elicited by dopamine recep-
tor stimulation. 
The present results suggest that the anti-dyskinetic 
effects of NOS inhibition at the dose tested do not sig-
nificantly impair normal motor performance and do not 
suffer tolerance over a period of 8 days. These observa-
tions open a new possible therapeutic approach to motor 
complications of chronic l-DOPA therapy in patients with 
Parkinson’s disease.
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